Efficacy and tolerance of betamethasone dipropionate propylene glycol for resistant psoriasis and other resistant steroid-responsive dermatoses.
Betamethasone dipropionate, 0.05%, in a propylene glycol ointment vehicle (Diprolene Ointment) was administered to forty-seven patients with resistant psoriasis or other resistant steroid-responsive dermatoses in a 2 week open study. The efficacy and tolerance of this new topical corticosteroid preparation were evaluated. Response was rapid, as illustrated by the sharp decrease in the severity of signs and symptoms. All patients improved. Lesions cleared in 25.5% of cases (twelve patients), showed marked improvement in 66% (thirty-one patients) and showed moderate improvement in 8.5% (four patients). Six patients developed folliculitis which did not necessitate discontinuation of Diprolene therapy. No changes in adrenal function were detected.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001623:Betamethasone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011536:Prurigo / Q000188:drug therapy; D011565:Psoriasis / Q000188:drug therapy*
C011175:betamethasone-17,21-dipropionate; D001623:Betamethasone